N/A
Completed N=254
Activating Collaborative CIS Support Via Targeted Provider Mailing
Precancerous Condition
Source: ClinicalTrials.gov NCT00873288 ↗
Enrolled (actual)
254
Serious AEs
0.0%
Results posted
Mar 2023
Primary outcomePrimary: Patient Satisfaction in the 2 Interventions — 11.79; 11.68 score on a scale — p=> 0.05
Summary
RATIONALE: Receiving a reminder letter from their doctor with questions to ask the Cancer Information Service may be more effective than a standard reminder letter in helping patients who have had an abnormal Pap test keep their follow-up colposcopy appointment.
PURPOSE: This randomized clinical trial is studying a personalized letter with Cancer Information Service support to see how well it works compared with a standard reminder letter in women scheduled for colposcopy after an abnormal Pap test.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patient Satisfaction in the 2 Interventions |
11.79; 11.68 | > 0.05 |
| PRIMARY CIS Experience of Patients in Arm II and the Effect of the Intervention on Their Follow-up Colposcopy |
— | — |
| SECONDARY Attendance at a Follow-up Colposcopy Appointment Within 6 Months of Their Pap Test |
107; 102 | 0.207 |
| SECONDARY Latency Between the Pap Test and the Colposcopy Appointment |
39.5; 42.5 | 0.66 |
| SECONDARY Number of CIS Callers Who Provided the Specific Codes Listed in the Intervention Letter |
— | — |
Eligibility Criteria
Inclusion criteria
DISEASE CHARACTERISTICS:
- Received an abnormal Pap test result
- Scheduled for a colposcopy within 6 months of their Pap test at either the Erie Family Health Center or the Prentice Ambulatory Clinic
PATIENT CHARACTERISTICS:
- Female
- Able to communicate in either English or Spanish
- Clinic staff will review patient charts to determine eligibility
PRIOR CONCURRENT THERAPY:
- Not specified
Exclusion criteria
- <18 years
- unable to communicate in English or Spanish
- no address to which a letter can be mailed
Data sourced from ClinicalTrials.gov (NCT00873288). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.